• Department of Ophthalmology, People′;
  • s Hospital of Peking University Department of Ophthalmology, People′;
  • s Hospital of Peking University Department of Ophthalmology, People′;
  • s Hospital of Peking University Department of Ophthalmology, People′;
  • s Hospital of Peking University;
Export PDF Favorites Scan Get Citation

Objective To evaluate the efficacy of intravitreal injection with Bevacizumab for iris neovascularization (INV) which caused by proliferative dia betic retinopathy (PDR) or central retinal vein occlusion (CRVO). Methods The clinical data of 39 patients (47 eyes) with INV who undergone intravitreal injection with Bevacizumab from 12,2006 to 3,2007 in Department of Ophthalmology, People prime;s Hospital of Peking University were retrospectively analyzed. The patients (22 males and 17 females, 23 left eyes and 24 right eyes) aged from 28 to 82 years with the average of (57.77 plusmn;13.0)years. 26 cases (34 eyes) were PDR and 13 cases (13 eyes) were CRVO. All of patients underwent intravitreal injection with 1.25 mg/0.05 ml Bevacizumab. Follow-up time was 1 day, 3 days, 1 week, 3 week s and 6 weeks after the treatment. The visual acuity, changes of intraocular pre ssure and changes of INV before and after the treatment were observed and analyzed. Results In patients with PDR, the visual acuity was improved in 19 eyes (55.9%), was stable in 15 eyes (44.1%) and none decreased. In patients with CRVO, the visual acuity was improved in 4 eyes (30.8%), was stable in 9 eyes (69.0%) and none decreased. Among neovascular glaucoma (NVG), decreas e of IOP was noticed in 16 eyes with PDR (80%) and 6 eyes with CRVO (667%). Re gression of INV was noticed in 97.1% PDR patients and 84.6% CRVO patients. Conclusions Intravitreal injection with Bevacizumab is very effective in treating INV. Further researches still needs to explore long term efficacy, safety and complications of this t reatment. (Chin J Ocul Fundus Dis,2008,24:176-179)

Citation: Kai Wang Yanrong Jiang Xiaoying Liang Xiaoxin Li. Clinical observation of intravitreal with Bevacizumab for iris neovascularization. Chinese Journal of Ocular Fundus Diseases, 2008, 24(3): 176-179. doi: Copy